The Phase Ib trial is set to test a gene therapy designed to target a rare disorder that causes muscle and respiratory failure.

Aro Biotherapeutics, a clinical-stage biotechnology company working to develop potent and tissue-targeted medicines, today announced the dosing of the first patient in its clinical trial of ABX1100, a ...

Elraglusib is aimed at treating pancreatic ductal adenocarcinoma. Credit: Jo Panuwat D/Shutterstock. Actuate Therapeutics has gained orphan medicinal product designation (OMPD) from the European ...

Actuate Therapeutics has gained orphan medicinal product designation (OMPD) from the European Medicines Agency (EMA) for elraglusib to treat pancreatic ductal adenocarcinoma (PDAC). The glycogen ...

07, 2025 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (NASDAQ: ACTU) (“Actuate” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment of ...

In this section, we will discuss the significance of phosphorylation modifications on several substrate proteins, including members of the mitogen-activated protein kinases family, small mothers ...

Over the past two decades, the idea of targeting transcription factors to combat malignancies has turned into a clinical ...

We describe aspirin as a cyclooxygenase inhibitor, atorvastatin as a 3-hydroxy-3-methylglutaryl (HMG) coenzyme A reductase inhibitor, and lithium as a glycogen synthase kinase 3β (GSK3β ...

Sphere of Influence. In iAssembloids, microglia (red) form projections (white arrows), while astrocytes (green) assume star shapes typically found in the brain. [Courtesy of Kampmann et al., 2025.] ...

Diabetes Care. 2013;36(4):1047-1055.